Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles.

Garland KM, Sevimli S, Kilchrist KV, Duvall CL, Cook RS, Wilson JT.

Cell Mol Bioeng. 2019 May 3;12(5):429-442. doi: 10.1007/s12195-019-00571-6. eCollection 2019 Oct.

PMID:
31719925
2.

Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.

Williams MM, Elion DL, Rahman B, Hicks DJ, Sanchez V, Cook RS.

Oncotarget. 2019 Oct 9;10(52):5389-5402. doi: 10.18632/oncotarget.27070. eCollection 2019 Sep 10.

3.

Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth In Vivo.

Hwang Y, Kim LC, Song W, Edwards DN, Cook RS, Chen J.

Cancer Res. 2019 Jul 1;79(13):3178-3184. doi: 10.1158/0008-5472.CAN-18-3658. Epub 2019 May 13.

PMID:
31085701
4.

Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids.

Sharick JT, Jeffery JJ, Karim MR, Walsh CM, Esbona K, Cook RS, Skala MC.

Neoplasia. 2019 Jun;21(6):615-626. doi: 10.1016/j.neo.2019.04.004. Epub 2019 May 9.

5.

Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor.

Elion DL, Cook RS.

Oncotarget. 2019 Mar 22;10(24):2338-2339. doi: 10.18632/oncotarget.26729. eCollection 2019 Mar 22. No abstract available.

6.

Author Correction: Drug response in organoids generated from frozen primary tumor tissues.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC.

Sci Rep. 2019 Apr 24;9(1):6517. doi: 10.1038/s41598-019-42133-w.

7.

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.

Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW.

J Med Chem. 2019 Apr 25;62(8):3971-3988. doi: 10.1021/acs.jmedchem.8b01991. Epub 2019 Apr 16.

PMID:
30929420
8.

Differential sensitivity of gastric and small intestinal muscles to inducible knockdown of anoctamin 1 and the effects on gastrointestinal motility.

Hwang SJ, Pardo DM, Zheng H, Bayguinov Y, Blair PJ, Fortune-Grant R, Cook RS, Hennig GW, Shonnard MC, Grainger N, Peri LE, Verma SD, Rock J, Sanders KM, Ward SM.

J Physiol. 2019 May;597(9):2337-2360. doi: 10.1113/JP277335. Epub 2019 Mar 28.

PMID:
30843201
9.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
10.

Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Axelrod ML, Cook RS, Johnson DB, Balko JM.

Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. doi: 10.1158/1078-0432.CCR-18-3200. Epub 2018 Nov 21. Review.

PMID:
30463850
11.

Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.

Werfel TA, Elion DL, Rahman B, Hicks DJ, Sanchez V, Gonzales-Ericsson PI, Nixon MJ, James JL, Balko JM, Scherle PA, Koblish HK, Cook RS.

Cancer Res. 2019 Jan 1;79(1):171-182. doi: 10.1158/0008-5472.CAN-18-1106. Epub 2018 Nov 9.

PMID:
30413412
12.

p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion.

Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA.

iScience. 2018 Oct 26;8:236-249. doi: 10.1016/j.isci.2018.09.018. Epub 2018 Sep 25.

13.

Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.

Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, Fedorova O, Pyle AM, Wilson JT, Cook RS.

Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.

14.

Efferocytosis in the tumor microenvironment.

Werfel TA, Cook RS.

Semin Immunopathol. 2018 Nov;40(6):545-554. doi: 10.1007/s00281-018-0698-5. Epub 2018 Sep 5. Review.

15.

Genetic and Phenotypic Diversification of Heterogeneous Tumor Populations.

Elion DL, Cook RS.

Trends Mol Med. 2018 Aug;24(8):655-656. doi: 10.1016/j.molmed.2018.06.003. Epub 2018 Jun 28.

PMID:
30060834
16.

Staphylococcus xylosus Cystitis and Struvite Urolithiasis in Nude Mice Implanted with Sustained-release Estrogen Pellets.

Salleng KJ, Jones CP, Boyd KL, Hicks DJ, Williams MM, Cook RS.

Comp Med. 2018 Aug 1;68(4):256-260. doi: 10.30802/AALAS-CM-18-000005. Epub 2018 Jul 17.

17.

Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.

Elion DL, Cook RS.

Oncotarget. 2018 Jun 22;9(48):29007-29017. doi: 10.18632/oncotarget.25626. eCollection 2018 Jun 22. Review.

18.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM.

Oncoimmunology. 2018 Mar 6;7(6):e1438106. doi: 10.1080/2162402X.2018.1438106. eCollection 2018.

19.

Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.

Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL.

Cancer Res. 2018 Apr 1;78(7):1845-1858. doi: 10.1158/0008-5472.CAN-17-2388. Epub 2018 Jan 22.

20.

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.

Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS.

Cell Death Dis. 2018 Jan 17;9(2):21. doi: 10.1038/s41419-017-0072-x.

21.

Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS.

Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Review.

22.

ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.

Williams MM, Vaught DB, Joly MM, Hicks DJ, Sanchez V, Owens P, Rahman B, Elion DL, Balko JM, Cook RS.

Breast Cancer Res. 2017 Sep 8;19(1):105. doi: 10.1186/s13058-017-0893-7.

23.

Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.

Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.

Breast Cancer Res. 2017 Jun 30;19(1):74. doi: 10.1186/s13058-017-0868-8.

24.

Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.

Walsh AJ, Cook RS, Skala MC.

J Nucl Med. 2017 Sep;58(9):1367-1372. doi: 10.2967/jnumed.117.192534. Epub 2017 Jun 6. Review.

25.

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

Song W, Hwang Y, Youngblood VM, Cook RS, Balko JM, Chen J, Brantley-Sieders DM.

Oncogene. 2017 Oct 5;36(40):5620-5630. doi: 10.1038/onc.2017.170. Epub 2017 Jun 5.

26.

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.

Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS.

Mol Cancer Res. 2017 Mar;15(3):259-268. doi: 10.1158/1541-7786.MCR-16-0280-T. Epub 2016 Dec 30.

27.

mTORC1 and mTORC2 in cancer and the tumor microenvironment.

Kim LC, Cook RS, Chen J.

Oncogene. 2017 Apr 20;36(16):2191-2201. doi: 10.1038/onc.2016.363. Epub 2016 Oct 17. Review.

28.

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS.

Cancer Res. 2016 Aug 15;76(16):4752-64. doi: 10.1158/0008-5472.CAN-15-3393. Epub 2016 Apr 25.

29.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):.

30.

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.

Oncogene. 2016 Mar 3;35(9):1206. doi: 10.1038/onc.2015.418. No abstract available.

PMID:
26935538
31.

Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine.

Manning HC, Buck JR, Cook RS.

J Nucl Med. 2016 Feb;57 Suppl 1:60S-8S. doi: 10.2967/jnumed.115.157917. Review.

32.

Drug response in organoids generated from frozen primary tumor tissues.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC.

Sci Rep. 2016 Jan 7;6:18889. doi: 10.1038/srep18889. Erratum in: Sci Rep. 2019 Apr 24;9(1):6517.

33.

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

Young CD, Arteaga CL, Cook RS.

Breast Cancer Res. 2015 Dec 4;17:148. doi: 10.1186/s13058-015-0656-2.

34.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.

35.

Clearance of dying cells accelerates malignancy.

Vaught DB, Cook RS.

Oncotarget. 2015 Sep 22;6(28):24590-1. doi: 10.18632/oncotarget.5670. No abstract available.

36.

Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS.

Oncogene. 2016 Mar 3;35(9):1143-52. doi: 10.1038/onc.2015.169. Epub 2015 Jul 6. Erratum in: Oncogene. 2016 Mar 3;35(9):1206.

37.

mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.

Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM.

PLoS Genet. 2015 Jul 1;11(7):e1005291. doi: 10.1371/journal.pgen.1005291. eCollection 2015 Jul.

38.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.

39.
40.

Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts.

Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC.

J Biomed Opt. 2015 Feb;20(2):26004. doi: 10.1117/1.JBO.20.2.026004.

41.

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M.

Cell Cycle. 2015;14(4):648-55. doi: 10.4161/15384101.2014.994966. Erratum in: Cell Cycle. 2015;14(8):1339-41.

42.

Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis.

Vaught DB, Stanford JC, Cook RS.

Cancer Cell Microenviron. 2015;2(1). pii: e666. doi: 10.14800/ccm.666.

43.

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS.

J Clin Invest. 2014 Nov;124(11):4737-52. doi: 10.1172/JCI76375. Epub 2014 Sep 24.

44.

Enhancing diversity in the public health research workforce: the research and mentorship program for future HIV vaccine scientists.

Sopher CJ, Adamson BJ, Andrasik MP, Flood DM, Wakefield SF, Stoff DM, Cook RS, Kublin JG, Fuchs JD.

Am J Public Health. 2015 Apr;105(4):823-30. doi: 10.2105/AJPH.2014.302076. Epub 2014 Aug 14.

45.

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC.

Cancer Res. 2014 Sep 15;74(18):5184-94. doi: 10.1158/0008-5472.CAN-14-0663. Epub 2014 Aug 6.

46.

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC.

Biomed Opt Express. 2014 Jun 16;5(7):2247-61. doi: 10.1364/BOE.5.002247. eCollection 2014 Jul 1.

47.

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.

J Clin Invest. 2014 May;124(5):2037-49. doi: 10.1172/JCI72522. Epub 2014 Apr 8.

48.

CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.

Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A.

Mol Biol Cell. 2014 Mar;25(5):566-82. doi: 10.1091/mbc.E13-07-0360. Epub 2014 Jan 8.

49.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.

50.

Mouse models and anti-HER2 therapies.

Hanker AB, Cook RS, Arteaga CL.

Oncotarget. 2013 Nov;4(11):1866-7. No abstract available.

Supplemental Content

Support Center